Cargando…
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
Haemolytic uraemic syndrome (HUS) remains a leading cause of paediatric acute kidney injury (AKI). Haemolytic uraemic syndrome is characterised by the triad of microangiopathic haemolytic anaemia, thrombocytopenia and AKI. In ~ 90% of cases, HUS is a consequence of infection with Shiga toxin-produci...
Autores principales: | Walsh, Patrick R., Johnson, Sally |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660499/ https://www.ncbi.nlm.nih.gov/pubmed/30058046 http://dx.doi.org/10.1007/s00467-018-4025-0 |
Ejemplares similares
-
Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab
por: Jeantet, Guillaume, et al.
Publicado: (2018) -
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017)